Hero image

OMJJARA ▼ (momelotinib) Mode of Action (MoA)

Omjjara targets JAK1, JAK2, and ACVR1. It is the only licensed JAK inhibitor with ACVR1 inhibition in the UK.1-4

Read on to learn more about the effects of JAK1/JAK2 and ACVR1 inhibition and view the mechanism of action video for Omjjara (momelotinib).

JAK1 and JAK2

Mode of action
  • OMJJARA inhibits wild‑type JAK1/JAK2 and mutant JAK2V617F, reducing downstream STAT activation1
  • Suppresses pro‑inflammatory signalling that drives myeloproliferation and symptom burden1
  • Result: Supports control of disease activity in MF1

ACVR1

Mode of action
  • OMJJARA directly inhibits ACVR1 → reduced SMAD1/5/8 signalling and lower liver hepcidin expression1,5
  • Lower hepcidin increases iron availability and supports red blood cell production1,5
  • Result: Linked improvement in anaemia‑related outcomes in MF patients with moderate to severe anaemia1-4

ACVR, activin A receptor; BMP, bone morphogenetic protein; EPOR, erythropoietin receptor; JAK, Janus kinase; MF, myelofibrosis; MPL, thrombopoietin receptor (myeloproliferative leukaemia protein); p, phosphorylation; SMAD, suppressor of mothers against decapentaplegic; STAT, signal transducer and activator of transcription

Please refer to the SmPC before prescribing.

INDICATION

Omjjara ▼ (momelotinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis (MF), post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis and who are:
1. Janus Kinase (JAK) inhibitor naïve
or
2. Have been treated with ruxolitinib.1

References

  1. OMJJARA UK, SmPC.
  2. Gupta V et al. Leuk Lymphoma. 2024;65(7):965-977.
  3. Gerds AT et al. Lancet Haematol. 2023;10:e735-e746.
  4. Verstovsek S et al. Lancet. 2023;401:269-280.
  5. Chifotides HT et al. J Hematol Oncol. 2022;15(1):7.

▶︎ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store.

Adverse events should also be reported to GSK on 0800 221 441, via email: uksafety@gsk.com or at https://gsk.public.reportum.com/

November 2026 | PM-GB-MML-WCNT-260010 (V1.0)